Zomig

How to order Zomig

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Zomig on Prescriptsy

Zomig is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Zomig is the brand name for zolmitriptan, a selective serotonin (5-HT1B/1D) receptor agonist (triptan) manufactured by Grünenthal.

It is used for the acute treatment of migraine attacks with or without aura in adults.

Zomig is available in 3 formulations: conventional tablets (Zomig 2.5 mg), orodispersible tablets (Zomig Rapimelt 2.5 mg), and nasal spray (Zomig Nasal Spray 5 mg per actuation).

This range of delivery options makes Zomig particularly suitable for patients who experience nausea, vomiting, or gastric stasis during migraine attacks.

Zomig is a prescription-only medicine (POM) in the United Kingdom.

Migraine is a common, disabling neurological condition affecting approximately 1 in 7 adults in the UK (over 10 million people).

Women are 3 times more likely to be affected than men, with peak prevalence between ages 25 and 55 during the most productive years of life.

Migraine is ranked as the sixth most disabling condition globally by the World Health Organization and the leading cause of disability in people under 50.

A typical migraine attack causes moderate to severe throbbing headache (usually unilateral), nausea and vomiting (occurring in 80% and 50% of attacks respectively), photophobia, phonophobia, and functional disability lasting 4 to 72 hours if untreated.

The economic impact is significant, with an estimated 25 million working days lost annually in the UK.

Triptans are the gold-standard acute treatment for moderate to severe migraine attacks.

This page provides a comprehensive clinical guide to Zomig, covering its mechanism of action, formulations, dosage, side effects, safety warnings, and how to obtain it in the United Kingdom.

Important safety information about Zomig

Before reading further, note these essential safety points about Zomig.

• Zomig is contraindicated in patients with ischaemic heart disease, previous stroke, peripheral vascular disease, or uncontrolled hypertension.
• Do not take Zomig within 24 hours of another triptan or ergotamine medication.
• Limit use to a maximum of 10 days per month to prevent medication overuse headache.
• Chest tightness is a recognised triptan class effect, not usually cardiac in origin. Severe or persistent chest pain should be investigated.
• If the first dose provides no relief, do not take a second dose for the same attack.

Understanding migraine

Migraine is a complex neurological disorder involving genetic predisposition, cortical hyperexcitability, and dysfunction of the trigeminovascular pain pathway. The migraine attack progresses through up to 4 phases.

The premonitory phase (experienced by approximately 60% of patients) involves hypothalamic activation producing symptoms such as yawning, fatigue, food cravings, neck stiffness, mood changes, and cognitive difficulty, occurring hours to days before the headache.

The aura phase (present in approximately 25 to 30% of migraineurs) is caused by cortical spreading depression, a slowly propagating wave of neuronal depolarisation followed by suppression, producing transient focal neurological symptoms lasting 5 to 60 minutes.

Visual aura is most common (scintillating scotoma, zigzag lines, visual field loss), followed by sensory aura (tingling in the hand or face) and speech disturbance.

The headache phase results from activation of the trigeminovascular system.

Trigeminal sensory neurons innervating the meninges and intracranial blood vessels release vasoactive neuropeptides, principally calcitonin gene-related peptide (CGRP), from their peripheral terminals.

CGRP causes meningeal vasodilation, neurogenic inflammation (plasma protein extravasation, mast cell degranulation), and sensitisation of the trigeminal nociceptive pathway.

Pain signals are transmitted via second-order neurons in the trigeminal nucleus caudalis to the thalamus and cortical pain-processing regions.

The postdrome phase follows the headache, with fatigue, cognitive difficulty, and mood changes lasting hours to days.

Understanding these phases helps explain why early treatment (before central sensitisation develops) is more effective.

How Zomig works

Zolmitriptan targets the trigeminovascular system through 3 complementary mechanisms.

First, activation of 5-HT1B receptors on meningeal and cerebral blood vessels causes selective cranial vasoconstriction, reversing the CGRP-mediated vasodilation that occurs during the headache phase.

This vasoconstriction is confined to cranial vessels and does not significantly affect systemic blood pressure.

Second, activation of presynaptic 5-HT1D receptors on trigeminal nerve terminals inhibits the further release of CGRP, substance P, and neurokinin A, reducing neurogenic inflammation.

Third, zolmitriptan penetrates the blood-brain barrier and inhibits pain signal transmission in the trigeminal nucleus caudalis, the central relay station for trigeminovascular pain processing in the brainstem.

The active metabolite N-desmethyl-zolmitriptan, formed by hepatic CYP1A2 metabolism, has similar potency at 5-HT1B/1D receptors and contributes to the overall therapeutic effect.

The combined effect of the parent compound and active metabolite provides sustained efficacy over the course of the migraine attack.

Zomig formulations

Zomig tablets (2.5 mg)

Conventional film-coated tablets swallowed with water. Oral bioavailability approximately 40%. Peak plasma concentration at 1 to 1.5 hours. Duration of therapeutic effect approximately 6 to 8 hours. Suitable for patients without significant nausea who can swallow tablets without difficulty.

Zomig Rapimelt (2.5 mg orodispersible tablets)

Wafer-thin tablets that dissolve on the tongue within seconds. No water is required for administration.

The dissolved drug is swallowed with saliva and absorbed from the gastrointestinal tract (not from the oral mucosa).

Bioequivalent to conventional tablets with a peak plasma concentration at approximately 3 hours.

The primary advantage is convenience and ease of administration during attacks when nausea makes conventional tablet swallowing unpleasant, or when water is unavailable.

Zomig Nasal Spray (5 mg per actuation)

Single-use spray device delivering 5 mg zolmitriptan into one nostril.

Approximately 30% of the dose is absorbed directly through the nasal mucosa, bypassing first-pass hepatic metabolism and the gastrointestinal tract.

The remaining 70% is swallowed and absorbed from the gut. Peak plasma concentration occurs at 15 minutes to 1 hour, earlier than oral formulations.

The nasal spray is the preferred formulation for patients with severe nausea, vomiting, or gastric stasis (delayed gastric emptying, which commonly accompanies migraine and impairs oral drug absorption).

The main disadvantage is an unpleasant bitter taste, reported by approximately 20% of users, caused by the solution dripping from the nasal cavity into the pharynx.

Clinical evidence for Zomig

Multiple randomised, double-blind, placebo-controlled trials have established the efficacy of zolmitriptan for acute migraine.

Zolmitriptan 2.5 mg achieves headache relief (reduction from moderate or severe to mild or none) at 2 hours in approximately 60 to 65% of patients, compared with 30 to 35% with placebo.

Pain-free response at 2 hours is approximately 30 to 35% with 2.5 mg and 35 to 40% with 5 mg, compared with 10 to 15% with placebo.

The nasal spray 5 mg achieves headache relief at 1 hour in approximately 50% of patients and at 2 hours in approximately 70%, with earlier onset of relief compared with oral formulations.

A large meta-analysis of triptan trials published in The Lancet compared the 7 available triptans.

Zolmitriptan was confirmed as effective and well-tolerated, with a therapeutic gain (response rate minus placebo rate) comparable to sumatriptan and almotriptan.

The availability of nasal spray and orodispersible formulations gives zolmitriptan a practical advantage in patients with prominent gastrointestinal symptoms.

NICE guideline CG150 on headaches recommends offering a triptan and an NSAID or paracetamol as acute migraine treatment, with the choice of specific triptan guided by individual response and preference.

Treating migraine effectively with Zomig

Take Zomig as early as possible after the migraine headache begins.

Early treatment (while pain is still mild) produces higher response rates than treatment delayed until pain is moderate or severe, because peripheral and central sensitisation have not yet fully developed.

Do not take Zomig during the aura phase, as efficacy during aura has not been established, and the headache phase may not follow every aura.

Combining Zomig with a non-steroidal anti-inflammatory drug (NSAID) such as ibuprofen 400 mg, naproxen 500 mg, or aspirin 900 mg improves response rates compared with either agent alone.

NICE recommends this combination approach.

An antiemetic (metoclopramide 10 mg or domperidone 10 mg) may be taken alongside if nausea is prominent, which also promotes gastric emptying and improves oral drug absorption.

If Zomig provides initial relief but the headache returns (recurrence), a second dose may be taken after at least 2 hours.

If the first dose provides no relief at all, a second dose for the same attack is unlikely to help, and alternative treatment (an NSAID if not already taken, or a different strategy) should be used.

Consistent failure to respond to Zomig across multiple attacks should prompt re-evaluation of the migraine diagnosis and consideration of trying a different triptan.

Preventing medication overuse headache

Medication overuse headache (MOH) develops when acute headache medications (including triptans, paracetamol, NSAIDs, opioids, and combination analgesics) are used too frequently.

For triptans, the threshold is use on 10 or more days per month for 3 or more consecutive months.

MOH presents as chronic daily or near-daily headache that paradoxically worsens despite increasing use of acute medication.

The management of MOH requires withdrawal of the overused medication (which may cause a temporary worsening lasting 1 to 2 weeks for triptans), combined with starting preventive therapy.

If you find yourself needing Zomig more than 2 to 3 times per week, discuss preventive treatment with your GP.

NICE-recommended preventive options include propranolol (40 to 240 mg daily), amitriptyline (10 to 50 mg at night), topiramate (50 to 100 mg daily), and CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab) for patients who have failed 3 or more conventional preventives (NICE TA764, TA1234).

Side effects of Zomig

Common side effects

Taste disturbance (particularly with the nasal spray), paraesthesia (tingling), warm sensations, triptan sensations (chest tightness, throat pressure, heaviness), dizziness, drowsiness, nausea, dry mouth, and muscle weakness.

Triptan sensations are benign in origin but should be distinguished from true cardiac chest pain. Nasal spray additionally causes transient nasal irritation and throat discomfort.

Serious but rare side effects

Coronary vasospasm, myocardial infarction, cardiac arrhythmias, and ischaemic colitis are extremely rare. Serotonin syndrome may occur with concurrent serotonergic drugs.

Call 999 if you experience severe, crushing, or persistent chest pain, sudden severe abdominal pain with bloody stools, or symptoms of serotonin syndrome.

Report suspected adverse reactions to the MHRA at yellowcard.mhra.gov.uk .

Warnings and precautions

Zomig is contraindicated in ischaemic heart disease, previous stroke or TIA, peripheral vascular disease, Wolff-Parkinson-White syndrome, uncontrolled hypertension, hemiplegic or basilar migraine, concurrent or recent (24 hours) use of other triptans or ergotamine, and use within 2 weeks of an MAOI.

Moderate to severe hepatic impairment: maximum 5 mg in 24 hours (tablets); nasal spray not recommended. CYP1A2 inhibitors: maximum 5 mg in 24 hours.

Pregnancy: avoid unless clearly necessary. Breastfeeding: avoid for 24 hours after a dose.

Driving: do not drive during a migraine attack or until the effects of Zomig have resolved.

How to get Zomig in the UK

Zomig is available on NHS prescription from your GP or an authorised online prescriber registered with the General Pharmaceutical Council (GPhC).

Generic zolmitriptan tablets and orodispersible tablets are widely available and are usually dispensed unless the branded product is specifically prescribed.

Zomig Nasal Spray is currently available only as the branded product.

The standard NHS prescription charge in England is 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Sources

• Zomig 2.5 mg Tablets, Summary of Product Characteristics (EMC)
• Zomig Nasal Spray 5 mg, Summary of Product Characteristics (EMC)
• Zolmitriptan, British National Formulary (BNF)
• NICE CG150: Headaches in over 12s
• Migraine, NICE CKS
• Migraine, NHS
• MHRA Yellow Card Scheme